Abstract

According to recent surveys, over half of American adults take at least one dietary supplement (DS), with usage increasing with age. Healthcare providers should be aware of which DS products their patients are taking in order to best manage their overall care. While DS can be used to complement and enhance the actions of traditional medicine, they may be contraindicated when taken concomitant with prescribed medications. Herein, example DS-drug interactions associated with common conditions are discussed, as well as two hypothetical applications of DS.

Keywords: dietary Supplement; Co-ingestion; FDA

References

1. Nutrition C. for F. S. and A. “Questions and Answers on Dietary Supplements”. FDA (2020).
2. Dwyer JT., et al. “Dietary Supplements: Regulatory Challenges and Research Resources”. Nutrients 10 (2018).
3. Dietary supplement regulation: FDA’s bitter pill”. The Lancet 393 (2019): 718.
4. Gahche JJ., et al. “Federal Monitoring of Dietary Supplement Use in the Resident, Civilian, Noninstitutionalized US Population, National Health and Nutrition Examination Survey”. Journal of Nutrition 148 (2018): 1436S-1444S.
5. Cowan AE., et al. “Dietary Supplement Use Differs by Socioeconomic and Health-Related Characteristics among U.S. Adults, NHANES 2011−2014”. Nutrients 10 (2018).
6. 2019 CRN Consumer Survey on Dietary Supplements: Consumer Intelligence to Enhance Business Outcomes | Council for Responsible Nutrition.
7. Dietary Supplement Usage High for All Ages-Including Millennials.
8. Bailey RL., et al. “Why US Adults Use Dietary Supplements”. JAMA Internal Medicine 173 (2013): 355-361.
9. Qato DM., et al. “Prevalence of Dietary Supplement Use in US Children and Adolescents, 2003-2014”. JAMA Pediatrics 172 (2018): 780-782.
10. Jun S., et al. “Dietary Supplement Use among U.S. Children by Family Income, Food Security Level, and Nutrition Assistance Program Participation Status in 2011-2014”. Nutrients 10 (2018).
11. Jou J and Johnson PJ. “Nondisclosure of Complementary and Alternative Medicine Use to Primary Care Physicians: Findings From the 2012 National Health Interview Survey”. JAMA Internal Medicine 176 (2016): 545-546.
12. Mehta DH., et al. “Herbal and dietary supplement disclosure to health care providers by individuals with chronic conditions”. The Journal of Alternative and Complementary Medicine 14 (2008): 1263-1269.
13. Kennedy J., et al. “Patient Disclosure about Herb and Supplement Use among Adults in the US. Evid.-Based Complement”. Evidence-based Complementary and Alternative Medicine 5 (2008): 451-456.
14. Ben-Arye E., et al. “Mind the gap: Disclosure of dietary supplement use to hospital and family physicians”. Patient Education and Counseling 100 (2017): 98-103.
15. Gardiner P., et al. “Medical reconciliation of dietary supplements: Don’t ask, don’t tell”. Patient Education and Counseling 98 (2015): 512-517.
16. Tarn DM., et al. “A cross-sectional study of provider and patient characteristics associated with outpatient disclosures of dietary supplement use”. Patient Education and Counseling 98 (2015): 830-836.
17. Tarn DM., et al. “Physician-Patient Communication about Dietary Supplements”. Patient Education and Counseling 91 (2013): 287-294.
18. Dickinson A., et al. “Physicians and nurses use and recommend dietary supplements: report of a survey”. Nutrition Journal 8 29 (2009).
19. Ashar BH and Rowland-Seymour A. “Advising patients who use dietary supplements”. The American Journal of Medicine 121 (2008): 91-97.
20. Pascale B., et al. “Dietary Supplements: Knowledge and Adverse Event Reporting Among American Medical Society for Sports Medicine Physicians”. Clinical Journal of Sport Medicine 26 (2016): 139-144.
21. Cellini M., et al. “Dietary supplements: physician knowledge and adverse event reporting”. Medicine and Science in Sports and Exercise 45 (2013): 23-28.
22. Asher GN., et al. “Common Herbal Dietary Supplement-Drug Interactions”. American Family Physician 96 (2017): 101-107.
23. Lebensohn P., et al. “Integrative Medicine in Residency: Feasibility and Effectiveness of an Online Program”. Family Medicine 49 (2017): 514-521.
24. Dietary Supplements: What You Need to Know.
25. Roblek T., et al. “Drug-drug interaction software in clinical practice: a systematic review”. European Journal of Clinical Pharmacology 71 (2015): 131-142.
26. Eichner AK., et al. “Essential Features of Third-Party Certification Programs for Dietary Supplements: A Consensus Statement”. Current Sports Medicine Reports 18 (2019): 178-182.
27. Tarn DM., et al. “Provider and patient expectations for dietary supplement discussions”. Journal of General Internal Medicine 29 (2014): 1242-1249.
28. Houston M. “Nutrition and Nutraceutical Supplements for the Treatment of Hypertension: Part III”. The Journal of Clinical Hypertension 15 (2013): 931-937.
29. Wang CZ., et al. “Herbal Medicines as Adjuvants for Cancer Therapeutics”. The American Journal of Chinese Medicine 40 (2012): 657-669.
30. Gerber W., et al. “Beneficial Pharmacokinetic Drug Interactions: A Tool to Improve the Bioavailability of Poorly Permeable Drugs”. Pharmaceutics 10 (2018).
31. Rahman H., et al. “Drug-Herb Interactions in the Elderly Patient with IBD: a Growing Concern”. Current Treatment Options in Gastroenterology 15 (2017): 618-636.
32. Colombo D., et al. “Cyclosporine and Herbal Supplement Interactions”. International Journal of Toxicology (2014).
33. Qu H., et al. “Effects of Coenzyme Q10 on Statin‐Induced Myopathy: An Updated Meta‐Analysis of Randomized Controlled Trials”. Journal of the American Heart Association 7 (2018).
34. Gurley BJ. “Pharmacokinetic Herb-Drug Interactions (Part 1): Origins, Mechanisms, and the Impact of Botanical Dietary Supplements”. Planta Medica 78 (2012): 1478-1489.
35. Gaston TE., et al. “Natural’ is not synonymous with ‘Safe’: Toxicity of natural products alone and in combination with pharmaceutical agents”. Regulatory Toxicology and Pharmacology 113 (2020): 104642.
36. Kanji S., et al. “Interactions of commonly used dietary supplements with cardiovascular drugs: a systematic review”. Systematic Reviews 1 (2012): 26.
37. Supplements, I. of M. (US) and N. R. C. (US) C. on the F. for E. the S. of D. Vulnerable Groups and Prevalence of Use. Dietary Supplements: A Framework for Evaluating Safety (National Academies Press (US) (2005).
38. Geller AI., et al. “Emergency Department Visits for Adverse Events Related to Dietary Supplements”. The New England Journal of Medicine 373 (2015): 1531-1540.
39. Qato DM., et al. “Changes in Prescription and Over-the-Counter Medication and Dietary Supplement Use Among Older Adults in the United States, 2005 vs 2011”. JAMA Internal Medicine 176 (2016): 473-482.
40. Levy I., et al. “Potential drug interactions with dietary and herbal supplements during hospitalization”. Internal and Emergency Medicine 12 (2017): 301-310.
41. Hilsden RJ., et al. “Use of complementary and alternative medicine by patients with inflammatory bowel disease”. Inflammatory Bowel Diseases 17 (2011): 655-662.
42. Masullo L., et al. “Complementary and alternative medicine use and nutrient intake among individuals with multiple sclerosis in the United States”. Journal of Community Health 40 (2015): 153-160.
43. Wilson PB. “Dietary supplementation is more prevalent among adults with arthritis in the United States population”. Complementary Therapies in Medicine 29 (2016): 152-157.
44. Greco CM., et al. “Updated Review of Complementary and Alternative Medicine Treatments for Systemic Lupus Erythematosus”. Current Rheumatology Reports 15 (2013): 378.
45. Zhao S., et al. “Complementary and Alternative Medicine Use in Rheumatoid Arthritis: Considerations for the Pharmacological Management of Elderly Patients”. Drugs Aging 34 (2017): 255-264.
46. Romiti N., et al. “Effects of Devil’s Claw (Harpagophytum procumbens) on the multidrug transporter ABCB1/P-glycoprotein”. Phytomedicine: International Journal of Phytotherapy and Phytopharmacology 16 (2009): 1095-1100.
47. Ferrucci LM., et al. “Factors related to the use of dietary supplements by cancer survivors”. The Journal of Alternative and Complementary Medicine 15 (2009): 673-680.
48. Jermini M., et al. “Complementary medicine use during cancer treatment and potential herb-drug interactions from a cross-sectional study in an academic centre”. Scientific Reports 9 (2019): 1-11.
49. Engdal S., et al. “Identification and Exploration of Herb-Drug Combinations Used By Cancer Patients: Integr”. Journal of Cancer Therapy (2009).
50. Alsanad SM., et al. “Cancer Patients at Risk of Herb/Food Supplement–Drug Interactions: A Systematic Review”. Phytotherapy Research 28 (2014): 1749-1755.
51. Fasinu PS and Rapp GK. “Herbal Interaction With Chemotherapeutic Drugs-A Focus on Clinically Significant Findings”. Frontiers in Oncology 9 (2019).
52. Yeung KS., et al. “Herb-Drug Interactions in Cancer Care”. Oncology Williston Park N 32 (2018): 516-520.
53. Gardiner P., et al. “Medication and Dietary Supplement Interactions among a Low-Income, Hospitalized Patient Population Who Take Cardiac Medications”. Evidence-Based Complementary and Alternative Medicine (2015): 429826.
54. Liperoti R., et al. “Herbal Medications in Cardiovascular Medicine”. Journal of the American College of Cardiology 69 (2017): 1188-1199.
55. Zabłocka-Słowińska K., et al. “Dietary Supplementation During Diabetes Therapy and the Potential Risk of Interactions”. Advances in Clinical and Experimental Medicine 23 (2014): 939-946.
56. Moore K. “Important Drug-Drug/Drug-Supplement Interactions with Type 2 Diabetes Medications”. Contemporary Clinical (2015).
57. Eyal S., et al. “Concomitant therapy in people with epilepsy: potential drug-drug interactions and patient awareness”. Epilepsy and Behavior 31 (2014): 369-376.
58. Bosak M., et al. “Use of dietary and herbal supplements in adult patients with epilepsy”. Epilepsy Research 156 (2019): 106168.
59. Kaiboriboon K., et al. “Understanding herb and dietary supplement use in patients with epilepsy”. Epilepsia 50 (2009): 1927-1932.
60. Wolfrath SC., et al. “Use of nutritional supplements in Parkinson’s disease patients”. Movement Disorders Journal - Movement Disorder Society . 21 (2006): 1098-1101.
61. Samuels N., et al. “Herbal medicine and epilepsy: Proconvulsive effects and interactions with antiepileptic drugs”. Epilepsia 49 (2008): 373-380.
62. Ladenheim D., et al. “Potential health risks of complementary alternative medicines in HIV patients”. HIV Medicine 9 (2008): 653-659.
63. Kalichman SC., et al. “Use of dietary supplements among people living with HIV/AIDS is associated with vulnerability to medical misinformation on the internet”. AIDS Research and Therapy 9 (2012): 1.
64. Jalloh MA., et al. “Dietary supplement interactions with antiretrovirals: a systematic review”. International Journal of STD and AIDS 28 (2017): 4-15.
65. Lee LS., et al. “Interactions between Natural Health Products and Antiretroviral Drugs: Pharmacokinetic and Pharmacodynamic Effects”. Clinical Infectious Diseases 43 (2006): 1052-1059.
66. Safety Reporting Portal.
67. Timbo BB., et al. “Dietary Supplement Adverse Event Report Data From the FDA Center for Food Safety and Applied Nutrition Adverse Event Reporting System (CAERS), 2004-2013”. Annals of Pharmacotherapy 52 (2018): 431-438.
68. Abe AM., et al. “Regulatory alerts for dietary supplements in Canada and the United States, 2005-13”. American Journal of Health-System Pharmacy 72 (2015): 966-971.
69. Clarke TC., et al. “Trends in the Use of Complementary Health Approaches Among Adults: United States, 2002-2012”. National Health Statistics Reports (2015): 1-16.
70. Coenzyme Q10. NCCIH.
71. López-Lluch G., et al. “Bioavailability of coenzyme Q10 supplements depends on carrier lipids and solubilization. Nutr. Burbank Los Angel”. City of California City 57 (2019): 133-140.
72. Zhang Y., et al. “Ubiquinol is superior to ubiquinone to enhance Coenzyme Q10 status in older men”. Food and Function 9 (2018) 5653-5659.
73. Pravst I., et al. “Comparative Bioavailability of Different Coenzyme Q10 Formulations in Healthy Elderly Individuals”. Nutrients 12 (2020).
74. Thent ZC., et al. “Role of Exercise in the Management of Diabetes Mellitus: the Global Scenario”. PLOS ONE 8 (2013): e80436.
75. Khazrai YM., et al. “Effect of diet on type 2 diabetes mellitus: a review”. Diabetes/Metabolism Research and Reviews 1 (2014): 24-33.
76. NCCIH.
77. Sriramajayam K., et al. “Cinnamon bark extract improves glucose metabolism and lipid profile in the fructose-fed rat, an animal model of insulin resistance”. Singapore Medical Journal 47 (2006).
78. Allen RW., et al. “Cinnamon Use in Type 2 Diabetes: An Updated Systematic Review and Meta-Analysis”. Annals of Family Medicine 11 (2013): 452-459.
79. Mang B., et al. “Effects of a cinnamon extract on plasma glucose, HbA, and serum lipids in diabetes mellitus type 2”. European Journal of Clinical Investigation 36 (2006): 340-344.
80. Office of Dietary Supplements - Dietary Supplement Fact Sheet: Chromium.
81. Wang Y., et al. “Effects of the resistant starch on glucose, insulin, insulin resistance, and lipid parameters in overweight or obese adults: a systematic review and meta-analysis”. Nutrition and Diabetes 9 (2019): 1-11.
82. Cheng LJ., et al. “A systematic review and meta-analysis: Vinegar consumption on glycaemic control in adults with type 2 diabetes mellitus”. Journal of Advanced Nursing 76 (2020): 459-474.
83. Brown AC. “An overview of herb and dietary supplement efficacy, safety and government regulations in the United States with suggested improvements. Part 1 of 5 series”. Food and Chemical Toxicology 107 (2017): 449-471.
84. Abourashed EA., et al. “Content Variation of Catechin Markers, Total Phenolics and Caffeine in Green Tea Dietary Supplements”. Journal of Dietary Supplements 13 (2016): 171-184.
85. Andrews KW., et al. “Dietary Supplement Ingredient Database (DSID) and the Application of Analytically Based Estimates of Ingredient Amount to Intake Calculations”. Journal of Nutrition 148 (2018):1413S-1421S.

Citation

Citation: Richard J Bloomer., et al. “Effectively Managing the Co-ingestion of Dietary Supplements and Prescription Drugs".Acta Scientific Nutritional Health 5.2 (2021): 161-170.

Copyright

Copyright: © 2021 Richard J Bloomer., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.